CAR T-cells

9:35
Treatment-changing advancements in CLL: BTK, BCL-2, CD20 & CAR T-cells
Kanti Rai
2:11
Cellular therapies in CLL: from transplant to CAR T-cells?
Jennifer Brown
1:07
Sequential therapy and drug resistance in CLL in the era of targeted agents
Stephan Stilgenbauer
3:00
CAR T-cells for multiple myeloma: update & what’s in store for ASH 2018
Jesus Berdeja
2:42
Toxicity profile for CAR T-cells in multiple myeloma
Jesus Berdeja
11:58
iwNHL day 2 highlights: bridging the gap to CAR T-cell therapy & precision medicine
Anas Younes et al.
11:13
CAR T-cells in lymphoma: where are we now?
David Maloney et al.
1:26
Future directions for MLL therapy
Rob Pieters
2:53
Follicular lymphoma: identifying high-risk patients
Nathan Fowler
3:33
Allogeneic CD123-targeting CAR T-cell for AML: risks and potential
Marina Konopleva
3:07
Finding the right targets for CAR T-cell therapy in AML
Marina Konopleva
3:39
CAR T-cells in CLL: the current landscape
William Wierda
1:56
Promising approaches and clinical trials in MDS
David Steensma
3:38
Anti-BCMA CAR T-cells in myeloma: what data do we have so far?
Yi Lin
5:47
Where in the treatment sequence should CAR T-cells be used for myeloma?
Andrew Spencer et al.
9:28
CAR T-cells in myeloma: exploratory targets & payment models
Andrew Spencer et al.
The content of VJHemOnc is intended for healthcare professionals